{"classes":[{"categories":[{"measurements":[{"comment":"NA = Not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"24.9","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"description":"The duration of response was defined as the time from the date that the response criteria are first met to the date that Progressive Disease was objectively documented or death (whichever occurs first). Participants who did not have disease progression were censored at their last valid assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Zanubrutinib (160 mg) administered BID until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor, which comes first.","id":"OG000","title":"Zanubrutinib"}],"paramType":"MEDIAN","populationDescription":"Safety Analysis Set: All participants who received any dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to 3 years and 6 months","title":"Duration Of Response","type":"SECONDARY","unitOfMeasure":"months"}